For an adult psoriasis patient receiving Skyrizi (risankizumab) 150 mg subcutaneously every 12 weeks, is it contraindicated to undergo IPL laser or microneedling, and what interval should be observed between the injection and the procedure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Skyrizi and Cosmetic Procedures: IPL Laser and Microneedling

Skyrizi (risankizumab) is not contraindicated with IPL laser or microneedling procedures. There are no specific warnings or restrictions in the FDA prescribing information regarding these cosmetic procedures 1.

Key Considerations

What the Evidence Shows

The FDA label for Skyrizi provides clear guidance on injection site precautions but does not list cosmetic procedures as contraindications. The only skin-related restriction states: "Do not inject into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis" 1. This refers to the injection site itself, not to procedural restrictions.

The AAD-NPF biologic guidelines address surgical procedures but do not mention cosmetic dermatologic procedures like IPL or microneedling 2. For surgical interventions, the guidelines recommend:

  • Low-risk procedures: Biologics can be continued without interruption
  • Moderate-to-high-risk procedures: Consider holding biologics 3-4 half-lives before surgery and resuming 1-2 weeks after if no complications 2

Practical Approach

For IPL laser and microneedling, you can proceed without timing restrictions relative to Skyrizi injections. However, apply standard procedural precautions:

  • Avoid treating active psoriatic plaques during the procedure
  • Ensure skin is not actively inflamed at the treatment site
  • Wait for any injection site reactions to resolve before performing procedures near recent injection sites (typically resolves within days)
  • Standard post-procedure wound care applies as with any patient

Rationale

Risankizumab has a 28-day half-life and is administered every 12 weeks for psoriasis 3. The drug works systemically by blocking IL-23, not through local skin effects that would interfere with wound healing from cosmetic procedures. Long-term safety data through 6 years shows no increased wound healing complications or skin infection risks that would preclude these procedures 4, 5.

Common Pitfall to Avoid

Do not confuse the injection site precautions (avoiding inflamed or psoriatic skin for the Skyrizi injection itself) with contraindications to other procedures. These are separate considerations.

References

Related Questions

When should Skyrizi (risankizumab) be discontinued during pregnancy and why?
Does Skyrizi (risankizumab) maintain efficacy for three months due to a long elimination half‑life, a prolonged pharmacodynamic effect, or both?
What are the next treatment options for a patient with moderate-to-severe plaque psoriasis who has failed Skyrizi (risankizumab) after an adequate trial?
Can risankizumab (Risankizumab) be used at any age for the treatment of moderate to severe plaque psoriasis?
What is the recommended dosing, screening, and safety monitoring for Skyrizi (risankizumab) in an adult with moderate-to-severe plaque psoriasis who has failed conventional systemic therapy?
What is the acute management of a suspected cardioembolic stroke, including imaging, anticoagulation, and antiplatelet therapy?
How should constipation be managed in a patient taking risperidone?
Which of the following statements about the Atkins diet is true: it is a traditional low‑fat diet, it utilizes the glycemic index, it begins with severe fat restriction, or it appears to cause greater short‑term weight loss than a traditional low‑fat diet?
What Section 504 accommodations are appropriate for an 8‑year‑old child with attention‑deficit/hyperactivity disorder (ADHD)?
What is the appropriate duration for using a prescribed ophthalmic ointment?
What is the recommended dose and dosing frequency of Pyralvex (topical solution) for oral mucosal lesions in patients aged 12 years and older?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.